세계의 근침윤성 방광암 치료 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for muscle-invasive bladder cancer (MIBC) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Muscle-invasive Bladder Cancer Therapeutics Market Size (2025E): USD 1341.2 Million
• Projected Market Value (2032F): USD 3655.4 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 15.4%

Muscle-invasive Bladder Cancer Therapeutics Market - Report Scope:

Muscle-invasive bladder cancer is an aggressive form of bladder cancer that typically requires multimodal treatment approaches, including surgery, chemotherapy, radiation therapy, and immunotherapy. The market for MIBC therapeutics is evolving rapidly, driven by the introduction of novel immuno-oncology agents, targeted therapies, and advanced diagnostic tools. Treatment paradigms are increasingly personalized, with the emergence of biomarker-based therapies and precision medicine playing a critical role in improving patient outcomes. The MIBC therapeutics market serves oncologists, urologists, hospitals, cancer specialty centers, and research institutions globally.

Market Growth Drivers:

The global muscle-invasive bladder cancer therapeutics market is propelled by several critical factors, including the increasing incidence of bladder cancer worldwide, especially among aging populations and individuals with risk factors such as smoking or chronic bladder inflammation. Advancements in immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), and the approval of new therapeutic agents are expanding treatment options and improving survival rates. Additionally, growing investments in oncology research, expanding clinical trials, and supportive regulatory frameworks for cancer drug development contribute to market growth. Enhanced awareness and earlier diagnosis of MIBC further support the adoption of advanced therapeutic solutions.

Market Restraints:

Despite the promising outlook, the muscle-invasive bladder cancer therapeutics market faces notable challenges. High treatment costs, limited access to advanced therapies in low- and middle-income countries, and adverse side effects associated with chemotherapy and immunotherapy can hinder market expansion. Furthermore, the complex nature of MIBC requires multidisciplinary treatment, which can be logistically and financially burdensome for healthcare systems and patients alike. Resistance to existing therapies and variability in patient responses present additional clinical and research challenges that must be addressed to optimize care delivery.

Market Opportunities:

The market presents substantial opportunities through ongoing clinical trials, next-generation sequencing (NGS) integration in diagnostics, and biomarker-driven therapy development. Personalized medicine, based on genetic profiling, offers significant potential for tailoring treatment strategies to individual patients. Emerging therapeutic modalities, such as antibody-drug conjugates and intravesical immunotherapy agents, are gaining attention. Partnerships between biopharmaceutical companies and academic research institutions, along with increasing government funding for oncology research, provide fertile ground for innovation. Expanding healthcare infrastructure and reimbursement coverage in developing regions also present untapped potential for market players.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the muscle-invasive bladder cancer therapeutics market globally?
• Which drug classes and treatment modalities are showing the most promise for MIBC management?
• How are emerging immuno-oncology therapies transforming the treatment landscape?
• Who are the key players in the MIBC therapeutics market, and what strategic initiatives are they undertaking?
• What are the future prospects and therapeutic breakthroughs expected in the MIBC treatment market?

Competitive Intelligence and Business Strategy:

These companies invest heavily in R&D to develop novel agents targeting the tumor microenvironment, immune checkpoints, and genetic mutations associated with MIBC. Collaborations with diagnostic companies for companion diagnostics, as well as acquisitions of promising biotech firms, are key strategies employed to broaden product portfolios and enhance therapeutic efficacy. Patient-centric approaches, real-world evidence generation, and digital health integration also play a vital role in driving market success.

Key Companies Profiled:

• Pfizer Inc.
• Merck KGaA
• AstraZeneca PLC
• Roche Holding AG (Genentech)
• Astella
• J&J (Janssen Biotech)
• Cipla Inc.
• Amneal Pharma
• Bristol Myers Squibb Co.
• Dr. Reddy's Laboratories, Inc.
• Gilead Sciences Inc.
• Endo Pharma
• UroGen Pharma, Inc.
• Teva Pharmaceuticals (Actavis)
• Hikma Pharmaceuticals
• Incyte

Muscle-invasive Bladder Cancer Therapeutics Market Research Segmentation:

Cancer Grade:

• Low-grade Bladder Cancer
• High-grade Bladder Cancer

Drug Type:

• Immunotherapy
  • * Bacillus Calmette-Guerin
  • * Avelumab
  • * Nivolumab
  • * Pembrolizumab
  • * Others
• Chemotherapy
  • * Mitomycin C
  • * Docetaxel
  • * Paclitaxel
  • * Cisplatin
  • * Others
• Targeted Therapy
  • * Erdafitinib
  • * Enfortumab Vedotin-ejfv
  • * Sacituzumab Govitecan
  • * Others

Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Muscle-invasive Bladder Cancer Therapeutics Market Snapshot 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Industry Developments and Key Market Events
• 1.5. Demand Side and Supply Side Analysis
• 1.6. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definitions
• 2.2. Value Chain Analysis
• 2.3. Macro-Economic Factors
  • 2.3.1. Global GDP Outlook
  • 2.3.2. Global Construction Industry Overview
  • 2.3.3. Global Mining Industry Overview
• 2.4. Forecast Factors - Relevance and Impact
• 2.5. COVID-19 Impact Assessment
• 2.6. PESTLE Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. Geopolitical Tensions: Market Impact
• 2.9. Regulatory and Technology Landscape

3. Market Dynamics

• 3.1. Drivers
• 3.2. Restraints
• 3.3. Opportunities
• 3.4. Trends

4. Price Trend Analysis, 2019-2032

• 4.1. Region-wise Price Analysis
• 4.2. Price by Segments
• 4.3. Price Impact Factors

5. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 5.1. Key Highlights
• 5.2. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Cancer Grade
  • 5.2.1. Introduction/Key Findings
  • 5.2.2. Historical Market Size (US$ Mn) Analysis by Cancer Grade, 2019-2024
  • 5.2.3. Current Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
    • 5.2.3.1. Low-grade Bladder Cancer
    • 5.2.3.2. High-grade Bladder Cancer
  • 5.2.4. Market Attractiveness Analysis: Cancer Grade
• 5.3. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Drug Type
  • 5.3.1. Introduction/Key Findings
  • 5.3.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2019-2024
  • 5.3.3. Current Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
    • 5.3.3.1. Immunotherapy
      • 5.3.3.1.1. Bacillus Calmette-Guerin
      • 5.3.3.1.2. Avelumab
      • 5.3.3.1.3. Nivolumab
      • 5.3.3.1.4. Pembrolizumab
      • 5.3.3.1.5. Others
    • 5.3.3.2. Chemotherapy
      • 5.3.3.2.1. Mitomycin C
      • 5.3.3.2.2. Docetaxel
      • 5.3.3.2.3. Paclitaxel
      • 5.3.3.2.4. Cisplatin
      • 5.3.3.2.5. Others
    • 5.3.3.3. Targeted Therapy
      • 5.3.3.3.1. Erdafitinib
      • 5.3.3.3.2. Enfortumab Vedotin-ejfv
      • 5.3.3.3.3. Sacituzumab Govitecan
      • 5.3.3.3.4. Others
  • 5.3.4. Market Attractiveness Analysis: Drug Type
• 5.4. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Distribution Channel
  • 5.4.1. Introduction/Key Findings
  • 5.4.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2019-2024
  • 5.4.3. Current Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
    • 5.4.3.1. Hospitals Pharmacies
    • 5.4.3.2. Retail Pharmacies
    • 5.4.3.3. Specialty Pharmacies
    • 5.4.3.4. Online Pharmacies
  • 5.4.4. Market Attractiveness Analysis: Distribution Channel

6. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2024
• 6.3. Current Market Size (US$ Mn) Forecast, by Region, 2025-2032
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia & Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. North America Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. North America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 7.4.1. Low-grade Bladder Cancer
  • 7.4.2. High-grade Bladder Cancer
• 7.5. North America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 7.5.1. Immunotherapy
    • 7.5.1.1. Bacillus Calmette-Guerin
    • 7.5.1.2. Avelumab
    • 7.5.1.3. Nivolumab
    • 7.5.1.4. Pembrolizumab
    • 7.5.1.5. Others
  • 7.5.2. Chemotherapy
    • 7.5.2.1. Mitomycin C
    • 7.5.2.2. Docetaxel
    • 7.5.2.3. Paclitaxel
    • 7.5.2.4. Cisplatin
    • 7.5.2.5. Others
  • 7.5.3. Targeted Therapy
    • 7.5.3.1. Erdafitinib
    • 7.5.3.2. Enfortumab Vedotin-ejfv
    • 7.5.3.3. Sacituzumab Govitecan
    • 7.5.3.4. Others
• 7.6. North America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 7.6.1. Hospitals Pharmacies
  • 7.6.2. Retail Pharmacies
  • 7.6.3. Specialty Pharmacies
  • 7.6.4. Online Pharmacies

8. Europe Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Europe Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 8.3.1. Germany
  • 8.3.2. Italy
  • 8.3.3. France
  • 8.3.4. U.K.
  • 8.3.5. Spain
  • 8.3.6. Russia
  • 8.3.7. Rest of Europe
• 8.4. Europe Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 8.4.1. Low-grade Bladder Cancer
  • 8.4.2. High-grade Bladder Cancer
• 8.5. Europe Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 8.5.1. Immunotherapy
    • 8.5.1.1. Bacillus Calmette-Guerin
    • 8.5.1.2. Avelumab
    • 8.5.1.3. Nivolumab
    • 8.5.1.4. Pembrolizumab
    • 8.5.1.5. Others
  • 8.5.2. Chemotherapy
    • 8.5.2.1. Mitomycin C
    • 8.5.2.2. Docetaxel
    • 8.5.2.3. Paclitaxel
    • 8.5.2.4. Cisplatin
    • 8.5.2.5. Others
  • 8.5.3. Targeted Therapy
    • 8.5.3.1. Erdafitinib
    • 8.5.3.2. Enfortumab Vedotin-ejfv
    • 8.5.3.3. Sacituzumab Govitecan
    • 8.5.3.4. Others
• 8.6. Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 8.6.1. Hospitals Pharmacies
  • 8.6.2. Retail Pharmacies
  • 8.6.3. Specialty Pharmacies
  • 8.6.4. Online Pharmacies

9. East Asia Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. East Asia Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. South Korea
• 9.4. East Asia Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 9.4.1. Low-grade Bladder Cancer
  • 9.4.2. High-grade Bladder Cancer
• 9.5. East Asia Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 9.5.1. Immunotherapy
    • 9.5.1.1. Bacillus Calmette-Guerin
    • 9.5.1.2. Avelumab
    • 9.5.1.3. Nivolumab
    • 9.5.1.4. Pembrolizumab
    • 9.5.1.5. Others
  • 9.5.2. Chemotherapy
    • 9.5.2.1. Mitomycin C
    • 9.5.2.2. Docetaxel
    • 9.5.2.3. Paclitaxel
    • 9.5.2.4. Cisplatin
    • 9.5.2.5. Others
  • 9.5.3. Targeted Therapy
    • 9.5.3.1. Erdafitinib
    • 9.5.3.2. Enfortumab Vedotin-ejfv
    • 9.5.3.3. Sacituzumab Govitecan
    • 9.5.3.4. Others
• 9.6. East Asia Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 9.6.1. Hospitals Pharmacies
  • 9.6.2. Retail Pharmacies
  • 9.6.3. Specialty Pharmacies
  • 9.6.4. Online Pharmacies

10. South Asia & Oceania Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. South Asia & Oceania Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 10.3.1. India
  • 10.3.2. Southeast Asia
  • 10.3.3. ANZ
  • 10.3.4. Rest of SAO
• 10.4. South Asia & Oceania Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 10.4.1. Low-grade Bladder Cancer
  • 10.4.2. High-grade Bladder Cancer
• 10.5. South Asia & Oceania Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 10.5.1. Immunotherapy
    • 10.5.1.1. Bacillus Calmette-Guerin
    • 10.5.1.2. Avelumab
    • 10.5.1.3. Nivolumab
    • 10.5.1.4. Pembrolizumab
    • 10.5.1.5. Others
  • 10.5.2. Chemotherapy
    • 10.5.2.1. Mitomycin C
    • 10.5.2.2. Docetaxel
    • 10.5.2.3. Paclitaxel
    • 10.5.2.4. Cisplatin
    • 10.5.2.5. Others
  • 10.5.3. Targeted Therapy
    • 10.5.3.1. Erdafitinib
    • 10.5.3.2. Enfortumab Vedotin-ejfv
    • 10.5.3.3. Sacituzumab Govitecan
    • 10.5.3.4. Others
• 10.6. South Asia & Oceania Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 10.6.1. Hospitals Pharmacies
  • 10.6.2. Retail Pharmacies
  • 10.6.3. Specialty Pharmacies
  • 10.6.4. Online Pharmacies

11. Latin America Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Latin America Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 11.3.1. Brazil
  • 11.3.2. Mexico
  • 11.3.3. Rest of LATAM
• 11.4. Latin America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 11.4.1. Low-grade Bladder Cancer
  • 11.4.2. High-grade Bladder Cancer
• 11.5. Latin America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 11.5.1. Immunotherapy
    • 11.5.1.1. Bacillus Calmette-Guerin
    • 11.5.1.2. Avelumab
    • 11.5.1.3. Nivolumab
    • 11.5.1.4. Pembrolizumab
    • 11.5.1.5. Others
  • 11.5.2. Chemotherapy
    • 11.5.2.1. Mitomycin C
    • 11.5.2.2. Docetaxel
    • 11.5.2.3. Paclitaxel
    • 11.5.2.4. Cisplatin
    • 11.5.2.5. Others
  • 11.5.3. Targeted Therapy
    • 11.5.3.1. Erdafitinib
    • 11.5.3.2. Enfortumab Vedotin-ejfv
    • 11.5.3.3. Sacituzumab Govitecan
    • 11.5.3.4. Others
• 11.6. Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 11.6.1. Hospitals Pharmacies
  • 11.6.2. Retail Pharmacies
  • 11.6.3. Specialty Pharmacies
  • 11.6.4. Online Pharmacies

12. Middle East & Africa Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 12.1. Key Highlights
• 12.2. Pricing Analysis
• 12.3. Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2025-2032
  • 12.3.1. GCC Countries
  • 12.3.2. South Africa
  • 12.3.3. Northern Africa
  • 12.3.4. Rest of MEA
• 12.4. Middle East & Africa Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
  • 12.4.1. Low-grade Bladder Cancer
  • 12.4.2. High-grade Bladder Cancer
• 12.5. Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
  • 12.5.1. Immunotherapy
    • 12.5.1.1. Bacillus Calmette-Guerin
    • 12.5.1.2. Avelumab
    • 12.5.1.3. Nivolumab
    • 12.5.1.4. Pembrolizumab
    • 12.5.1.5. Others
  • 12.5.2. Chemotherapy
    • 12.5.2.1. Mitomycin C
    • 12.5.2.2. Docetaxel
    • 12.5.2.3. Paclitaxel
    • 12.5.2.4. Cisplatin
    • 12.5.2.5. Others
  • 12.5.3. Targeted Therapy
    • 12.5.3.1. Erdafitinib
    • 12.5.3.2. Enfortumab Vedotin-ejfv
    • 12.5.3.3. Sacituzumab Govitecan
    • 12.5.3.4. Others
• 12.6. Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
  • 12.6.1. Hospitals Pharmacies
  • 12.6.2. Retail Pharmacies
  • 12.6.3. Specialty Pharmacies
  • 12.6.4. Online Pharmacies

13. Competition Landscape

• 13.1. Market Share Analysis, 2025
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles
  • 13.3.1. Pfizer Inc.
    • 13.3.1.1. Company Overview
    • 13.3.1.2. Product Portfolio/Offerings
    • 13.3.1.3. Key Financials
    • 13.3.1.4. SWOT Analysis
    • 13.3.1.5. Company Strategy and Key Developments
  • 13.3.2. Merck KGaA
  • 13.3.3. AstraZeneca PLC
  • 13.3.4. Roche Holding AG (Genentech)
  • 13.3.5. Astella
  • 13.3.6. J&J (Janssen Biotech)
  • 13.3.7. Cipla Inc.
  • 13.3.8. Amneal Pharma
  • 13.3.9. Bristol Myers Squibb Co.
  • 13.3.10. Dr. Reddy's Laboratories, Inc.
  • 13.3.11. Gilead Sciences Inc.
  • 13.3.12. Endo Pharma
  • 13.3.13. UroGen Pharma, Inc.
  • 13.3.14. Teva Pharmaceuticals (Actavis)
  • 13.3.15. Hikma Pharmaceuticals

14. Appendix

• 14.1. Research Methodology
• 14.2. Research Assumptions
• 14.3. Acronyms and Abbreviations